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ABSTRACT  
Dendritic cell (DC)-based cancer vaccines, where the patient’s own immune system is 
harnessed to target and destroy tumor tissue, has emerged as a potent therapeutic 
strategy. In the development of such DC vaccines, it is crucial to load the DCs with tumor 
antigens, and to simultaneously activate them to become more potent antigen-presenting 
cells. For this, we report on microbubbles, loaded with both antigen mRNA as well as 
immunomodulating TriMix mRNA, which can be used for the ultrasound-triggered 
transfection of DCs. In vivo experiments with in vitro sonoporated DCs, show the effective 
induction of antigen-specific T cells, resulting in specific lysis of antigen-expressing cells. 
Especially in a therapeutic setting, sonoporation with TriMix has a significant added value, 
resulting in a significant reduction of tumor outgrowth and a marked increase in overall 
survival. What is more, complete tumor regression was observed in 30% of the 
antigen+TriMix DC vaccinated animals, which also displayed long-term antigen-specific 
immunological memory. As a result, DC sonoporation using microbubbles loaded with a 
combination of antigen and TriMix mRNA can elicit powerful immune responses in vivo, 
and might serve as a potential tool for further in vivo DC vaccination applications.  
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INTRODUCTION 
Since its discovery in the early ‘70s by Noble Prize winner Ralph M. Steinman, the 
dendritic cell (DC) came to be known as nature’s adjuvant [1]. Its unique capacity to 
present antigens and initiate antigen-specific T cell responses, makes the DC an 
interesting target in cancer immunotherapy. By modifying DCs to present tumor-derived 
antigens to T cells, the patient’s own immune system can be harnessed in the battle 
against the tumor [2]. For such a DC-based vaccine to be effective, two major 
requirements need to be satisfied. Firstly, the immune system should be able to 
discriminate between healthy tissue and cancer cells. For this, it is crucial to load DCs 
with cancer-specific tumor associated antigens (TAAs) [3, 4]. Upon presentation of these 
TAAs in major histocompatibility complexes (MHC) on the DC surface, TAA-specific 
immune responses can be mounted. Secondly, DCs should receive additional stimulation 
to become fully mature antigen-presenting cells that can provide the necessary co-
stimulatory signals to activate antigen-specific T cells.  
TAA-loading of DCs can be achieved in various ways: whole-tumor vaccines have been 
produced, as well as strategies based on isolated or recombinant TAA protein, antigenic 
peptides, and nucleic acid sequences encoding the antigens. Especially the use of TAA 
mRNA is appealing, as it offers several advantages [5]. First of all, using mRNA encoding 
full-length TAAs allows the DCs to present multiple epitopes to T cells, thus broadening 
the immune responses. Secondly, mRNA translation into protein occurs within the cytosol, 
resulting in preferential presentation of antigenic peptides via the MHC class I pathway. 
This will allow the presented antigens to be recognized by CD8+ T cells, resulting in the 
induction of cytotoxic T lymphocytes (CTL) that can cause TAA-specific lysis of tumor 
cells. In addition, the fact that mRNA does not need to cross the nuclear membrane 
represents an important advantage over plasmid DNA. Transfection with mRNA can 
therefore be performed in non-dividing cells (such as DCs) leading to fast and transient 
protein expression [6]. Moreover, by using mRNA, the risks of inducing insertional 
mutagenesis, which is considered a major drawback of DNA-based gene therapy, can be 
avoided.  
After antigen introduction, it is essential that the DCs undergo a process called 
“maturation” in order for antigen-presentation to effectively result in T cell activation. 
Maturation is initiated when DCs encounter “danger” signals, such as toll like receptor 
(TLR) agonists, causing them to shift in phenotype and function from antigen-capturing to 
antigen-presenting cells [7]. This is an absolute necessity for a DC-based cancer vaccine 
to be successful, as it is now clear that mature DCs are capable of inducing immunity 
against the presented antigens (i.e. stimulation of effector T cells), whereas their immature 
counterparts will rather induce tolerance (i.e. T cell anergy and regulatory T cells) [8]. The 
main reason for this is that immature DCs lack co-stimulatory molecules required for 
effective T cell activation [9]. Therefore, it is crucial to not only deliver antigens to DCs, 
but also maturation stimuli to ensure optimal immune activation by the DC vaccine.  
To respond to these requirements, we established a novel transfection method that offers 
possibilities for image-guided loading of DCs with antigen mRNA in vivo: mRNA-
sonoporation. This technique makes use of microbubbles, that consist of a gas core which 
is surrounded by a stabilizing lipid or polymer shell, and are known in the clinic as contrast 
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agents for ultrasound imaging [10]. Besides imaging, they are currently under 
investigation for the ultrasound-triggered delivery of drugs and genes: when ultrasound is 
applied to microbubbles, their gas core starts to oscillate, and can eventually implode 
when the ultrasound intensities are sufficiently high. Both the stable oscillations but 
especially microbubble implosion can be used to temporarily disrupt neighboring cell 
membranes in a process called sonoporation. Through these membrane pores, 
macromolecules and nanoparticles can be delivered directly into the cell’s cytoplasm [11, 
12]. We previously showed that by using microbubbles that are loaded with mRNA-
lipoplexes (i.e. complexes of mRNA and cationic liposomes), we could induce fast and 
efficient, ultrasound-triggered mRNA-loading of murine bone marrow-derived DCs in vitro, 
without important negative repercussions on the DC viability and capacity to respond to 
maturation stimuli [13]. Interestingly, Sever and colleagues reported that upon intradermal 
injection of SonoVue® microbubbles around the lesions of breast cancer patients, they 
drain to the lymphatics and appear in the tumor-draining lymph nodes [14, 15]. This not 
only makes them useful for the non-invasive identification of the sentinel lymph node, but 
could also pave the way for intranodal sonoporations using our mRNA-loaded 
microbubbles. In this way, mRNA sonoporation could be performed on intranodal DCs 
under image-guidance, and an off-the-shelf cancer vaccine could be produced.  
In this study, we aimed to evaluate the capacity of mRNA sonoporated DCs to induce 
immune responses in vivo. Moreover, to address the second DC vaccine requirement, we 
aimed to obtain both antigen-loading and stimulation of maturation by a single step 
sonoporation. This is important, as we previously reported that mRNA sonoporation 
without inclusion of additional immune stimulants merely induces partial maturation of the 
DCs. Therefore, we performed sonoporations with antigen mRNA and TriMix mRNA. 
TriMix is a mixture of 3 mRNAs, encoding CD40-ligand, a constitutively active form of 
TLR4 and CD70 (a co-stimulatory molecule required for effective CD8+ T cell priming) 
[16]. Co-delivery of these 3 nucleic acid sequences was already shown to modulate the 
DCs’ functionality, resulting in APCs that display a more mature, T cell activating 
phenotype [17]. Previous studies have demonstrated the superiority of TriMix over other, 
more conventional, maturation stimuli after intranodal injection of TAA and TriMix mRNA 
in tumor-bearing mice [18]. Also in a clinical setting, vaccination with DCs electroporated 
with TAA and TriMix mRNA lead to the induction of durable antitumor responses in a 
chemorefractory melanoma patient [19, 20]. On the basis of these results, we evaluated 
the potential of simultaneous delivery of TAA mRNA and TriMix via microbubbles and 
ultrasound to induce potent antitumor immune responses in mice, as schematically 
depicted in Figure 1A.  
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Figure 1. mRNA sonoporation of DCs using mRNA-loaded microbubbles and ultrasound. 
(A) Schematic representation of the use of mRNA-loaded microbubbles, which implode upon 
exposure to ultrasound and sonoporate the DCs. As a result, both antigen and DC modulating 
proteins are produced by the DC, which can lead to antigen presentation and T cell activation. 
(B) Schematic representation of the production of mRNA-loaded microbubbles. Antigen and 
TriMix mRNA are first mixed and complexed to biotinylated cationic liposomes. The resulting 
mRNA-lipoplexes can then be attached to the surface of avidinylated lipid microbubbles. 
MATERIALS AND METHODS 
Cell culture and mice  
Primary murine bone marrow-derived DC (BM-DC) cultures were generated from 
C57BL/6 mice. Female C57BL/6 mice were purchased from Harlan (Gannat, France) and 
housed in an SPF facility according to the regulations of the Belgian law and the local 
Ethical Committee. Mice were sacrificed and bone marrow was flushed from the hind 
limbs. After red blood cell lysis (Pharm Lyse Buffer, BD Biosciences, Erembodegem, 
Belgium), the collected cells were seeded in 100 mm not TC-treated polystyrene culture 
dishes (Corning®, Amsterdam, The Netherlands) at 2x106 cells ml-1 in 15 ml. The cell 
culture medium used was RPMI 1640 (Gibco-Invitrogen, Merelbeke, Belgium) 
supplemented with penicillin/streptomycin/L-glutamine (1%, Gibco-Invitrogen), β-
mercaptoethanol (50 µM, Gibco-Invitrogen), 5% FetalClone™ I (FCI, 5%, HyCloneTM) and 
recombinant murine GM-CSF (20 ng ml-1, Peprotech, Rock Hill, NJ). On day 3 of the 
culture, an additional 15 ml complete culture medium containing GM-CSF (40 ng ml-1) 
was added. On day 5, all cells were collected by centrifugation (5 min at 300 g), 
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resuspended in the appropriate culture medium at 5x105 cells ml-1 and seeded per 10 ml 
in OptiCellsTM (Nunc, Thermo Scientific, Aalst, Belgium) for sonoporation the next day. 
The mouse melanoma cell line MO4 (kindly provided by K. Rock, University of 
Massachusetts Medical Center) and the T cell lymphoma E.G7-OVA (obtained from the 
American Type Culture Collection, Rockville, MD, USA) were cultured at 37°C in a 
humidified 5% CO2 atmosphere in RPMI 1640 medium (Sigma-Aldrich, Diegem, Belgium) 
supplemented with 5% FCI, 100 U ml-1 penicillin, 100 µg ml-1 streptomycin, 2 mM L-
glutamine, 1 mM sodium pyruvate and nonessential amino acids (Sigma-Aldrich).  
C57BL/6 and OT-I mice for in vivo experiments were ordered from Charles River 
(L'Arbresle, France) and housed in SPF facilities according to the regulations of the 
Belgian law and the local Ethical Committee.  
Messenger RNA 
The vector, pST1 was provided by U. Sahin (Johannes- Gutenberg University, Mainz, 
Germany). The vectors pGEM-Ii80tOVA, pST1-eGFP-bis, pST1-caTLR4, pST1-mouse 
CD40-L and pST1-mouse CD70 were previously described [16, 18, 21]. Before in vitro 
transcription, pGEM and pST1 vectors were linearized with the restriction enzymes Spe I 
and Sap I, respectively. All enzymes were purchased from Fermentas (Vilnius, Lithuania). 
The in vitro transcription of mRNA and its subsequent quality control were performed as 
previously described [21]. 
In vitro mRNA sonoporation 
Lipid microbubbles loaded with mRNA-lipoplexes were prepared as described previously 
[13]. A schematic representation of the material production is shown in Figure 1B. Briefly, 
perfluorobutane (F2 chemicals, Preston, UK) microbubbles stabilized by a lipid coat 
consisting of DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine) (Lipoid, Ludwigshafen, 
Germany) and DSPE-PEG-biotin [1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[biotin(polyethylene glycol)-2000] (Avanti Polar Lipids, Alabaster, AL) in a 85:15 molar 
ratio were prepared. These biotinylated microbubbles were subsequently coated with 
avidin (Cell Sciences, Canton, USA), to allow coupling to biotin-containing mRNA 
lipoplexes. The mRNA lipoplexes were prepared by mixing mRNA with cationic liposomes 
consisting of 48.75% DOTAP (1,2-dioleoyl-3-trimethylammonium-propane), 48.75% 
DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine) and 2.5% DSPE-PEG-2000-
biotin [1,2-distearoyl-sn-glycero-3-phosphoethanol-amine-N-[biotinyl(polyethylene 
glycol)-2000] (all Avanti Polar Lipids), at a cationic lipid-to-mRNA charge (N/P) ratio of 8 
in OptiMem® (Gibco Invitrogen). When multiple mRNAs were used, these were first pre-
mixed in a 1:1 ratio prior to complexation to the cationic liposomes. The resulting mRNA-
lipoplexes (corresponding to 10 µg mRNA when GFP or OVA were used alone, or 40 µg 
when co-sonoporations with TriMix were performed) were incubated with the 
microbubbles for 5 min prior to use. After injection of mRNA lipoplex-loaded microbubbles 
in the OptiCellsTM, ultrasound was applied using a Sonitron 2000 (Artison, Inola, USA) 
(1 MHz, 2 W cm-² corresponding to a peak-negative-pressure of 800 kPa, 20% duty cycle 
(2 ms on, 8 ms off), 30 s total insonation time per OptiCellTM).  
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BM-DC antibody staining and flow cytometric analysis 
To evaluate the impact of mRNA sonoporation on the transfection efficiency and DC 
phenotype, the mRNA sonoporated cells were collected 24 h or 48 h after ultrasound 
application. The cells were washed and surface-stained with anti-CD11c-APC (BM-DC 
marker, Affymetrix eBioscience, Vienna, Austria) and anti-CD40-PE (Affymetrix), anti-
CD86-PE (BD biosciences) or anti-CD70-PE (Affymetrix) for 45 min at 4°C in the dark. 
After washing, the cells were resuspended in FACS buffer (phosphate buffered saline 
(PBS, Gibco-invitrogen), supplemented with 5% bovine serum albumin (BSA, Sigma-
Aldrich)) and analyzed using a FACSCaliburTM (BD) equipped with CellQuestTM software.  
Vaccination of mice with mRNA sonoporated DCs 
After in vitro mRNA sonoporation, the DCs were incubated for 2 h at 37°C in the 
OptiCellsTM. Then, all the cells (both the cells in suspension as well as the cells that grow 
adherent to the OptiCellTM membranes) were collected, and washed twice with PBS. 
Finally, the cells were resuspended at 2x106 cells ml-1 in PBS, of which 50 µl was injected 
s.c. into the flank of the mice.  
In vivo T cell proliferation assay 
In order to assess the potential of mRNA sonoporated DCs to efficiently induce 
proliferation of antigen-specific T cells, an in vivo OT-I proliferation assay was performed. 
This assay uses OVA as a model antigen, and is based on adoptive transfer of OT-I cells, 
which carry a transgenic CD8 T cell receptor which specifically recognizes the MHC I 
restricted OVA peptide SIINFEKL. For this, spleens from OT-I mice were processed into 
a single-cell suspension. After red blood cell lysis, CD8+ T cells were isolated via 
magnetically activated cell sorting, using a MACS CD8a T cell isolation kit (MACS Miltenyi, 
Leiden, The Netherlands) according to the manufacturer’s instructions. The collected 
CD8+ T cells were fluorescently labeled using carboxyfluorescein diacetate succinimidyl 
ester (CFSE, Molecular probes, 10 µM in PBS supplemented with 0.1% BSA) for 15 min 
at 37°C. After washing the cells with RPMI medium, the cells were resuspended at 1x108 
cells ml-1 in PBS. All mice received 200 µl of this CFSE-labeled OT-I cell suspension i.v. 
via tailvein injection. The next day, the mice received s.c. injections with PBS (negative 
control) or mRNA sonoporated DCs, as described previously. 5 days after vaccination, 
the mice were sacrificed and the inguinal lymph nodes were collected. After 30 min 
digestion of the nodes in liberase TL (100 µl, Roche, Vilvoorde, Belgium), a single-cell 
suspension was prepared. Half of the cells were used for flow cytometric analysis of 
proliferation (using a FACSCanto flow cytometer with FACSDivaTM software, BD 
Biosciences). On the other half of the suspension, a CD8+ T cell sort was performed. The 
resulting cells were resuspended at 2x106 cells ml-1 in RPMI medium and seeded per 
100 µl in a round-bottom 96 well plate for restimulation. To this extent, day 6 BM-DCs 
were loaded with 1 µg ml-1 SIINFEKL peptide (Eurogentec, Seraing, Belgium) for 30 min 
at 37°C. After washing, 100 µl SIINFEKL-pulsed DCs, suspended at 2x105 cells ml-1 were 
added to the OT-I cells in the 96 well plates for 24 h at 37°C.  
In vivo cytotoxic T lymphocyte assay 
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To investigate the potential of mRNA sonoporated DCs to induce antigen-specific CTL 
responses, an in vivo CTL assay was performed using an OVA model. For this, 5 days 
after vaccination with mRNA sonoporated DCs, the vaccinated mice were challenged i.v. 
with both target cells and control cells in a 1:1 ratio. The injected cells were splenocytes 
of untreated C57BL/6 mice that were either labeled with CFSE at low intensity (CFSElo 
control cells, 5x106 cells per injection), or labeled with CFSE at high intensity and 
additionally pulsed with the peptide SIINFEKL (CFSEhi target cells, 5x106 cells per 
injection). The next day, the mice were sacrificed, inguinal lymph nodes were collected, 
processed into a single-cell suspension, and analyzed for CFSE staining via flow 
cytometry using a BD FACSCanto. Mice injected s.c. with PBS served as non-immunized 
controls. The percentage specific lysis of target cells was calculated as (1–
((%CFSEhi/%CFSElo)immunized/(%CFSEhi/%CFSElo)non-immunized)x100%.  
In vivo therapeutic vaccination experiments 
The therapeutic potential of mRNA sonoporated DCs to reduce tumor growth was 
evaluated by performing therapeutic vaccinations in tumor-bearing mice. For this, 
C57BL/6 received a s.c. injection of 3x105 MO4 or E.G7-OVA tumor cells (suspended in 
PBS) in the flank. 10 days after tumor inoculation, when the lesions were palpable, the 
mice were randomized in different treatment groups based on tumor volume, and 
vaccinated with mRNA sonoporated DCs. A second therapeutic vaccination was 
performed at day 13 or 14 after tumor cell injection. Tumor growth was measured every 
other day using a caliper. When the tumor volume exceeded 1500 mm³, the mice were 
euthanized via cervical dislocation. Animals that completely rejected their tumors were 
rechallenged with 3x105 E.G7-OVA tumor cells, and subsequently with 3x105 MO4 cells. 
As controls for the rechallenge study, naïve (non-vaccinated) C57BL/6 were used.  
ELISA measurements 
Supernatants of mRNA sonoporated DCs were screened for the presence of IL-10 and 
IL-12p70. Supernatants of DC and T cell co-cultures were assayed for IFNγ. Cytokine 
measurements were performed via ELISA (all Ready-SET-Go!® ELISA kits, Affymetrix) 
according to the manufacturer’s instructions. 
Statistical analysis 
A one-way ANOVA followed by a Bonferroni multiple comparison test, was carried out 
(GraphPad software, la Jolla, CA, USA). Sample sizes and number of times experiments 
were repeated are indicated in the figure legends. The results are shown in column graphs 
as mean  standard deviation. The number of asterisks in the figures indicates the 
statistical significance as follows: *, p < 0.05; **, p < 0.01; ***, p < 0.001. Survival was 
visualized in a Kaplan-Meier plot. Differences in survival were analyzed by the log-rank 
(Mantel-Cox) test. 
RESULTS 
Transfection efficiency and phenotype of mRNA sonoporated DCs 
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In our previous report, we demonstrated that sonoporation could be used for ultrasound-
triggered transfection of primary DCs with mRNA in vitro. In addition, the sonoporation 
procedure as such, without the use of additional maturation stimuli, was shown to readily 
induce a small but significant shift in the expression of the DC maturation markers CD40 
and CD86 [13]. However, compared to a positive control where the DCs’ TLR4 was 
stimulated by incubation with bacteria-derived lipopolysaccharide (LPS), this maturation 
was merely partial. As complete DC maturation is warranted for effective 
immunostimulation, this prompted us to include additional stimuli to further increase the 
expression of co-stimulatory markers. Therefore, we included TriMix mRNA into the 
antigen mRNA-containing lipoplexes. We evaluated the effect of TriMix inclusion on the 
transfection efficiency as well as the DC phenotype, by analyzing the expression of 3 
molecules involved in T cell activation by DCs 24 h after sonoporation with either reporter 
mRNA alone (GFP) or in combination with TriMix (GFP+TriMix).  
 
Figure 2. Transfection efficiency and phenotypical analysis of DCs after mRNA 
sonoporation. 24 h after treatment of the DCs by sonoporation with GFP mRNA alone (GFP) or 
in combination with TriMix (GFP+TriMix), the cells were analyzed for the expression of GFP and 
different maturation markers (CD40, CD86 and CD70). DCs were gated based on CD11c 
staining. Untreated cells and LPS-stimulated cells served as negative and positive controls, 
respectively (n=3). 
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In accordance with our previous report, the results in Figure 2 indicate efficient 
transfection with GFP mRNA, resulting in 19% GFP-expressing DCs 24 h after 
sonoporation. Inclusion of TriMix results in a decrease in transfection efficiency to 11%. 
With regards to the DC phenotype, we observed a significant up-regulation of CD86 and 
CD40 expression in the GFP group compared to blank. The effects on CD70 expression 
are less pronounced. Sonoporation with GFP+TriMix, lead to a slight but significant 
additional increase in the expression of CD40, CD86 and CD70 over sonoporation with 
GFP mRNA alone. However, the expression levels of these surface molecules after 
GFP+TriMix sonoporation are still significantly lower in comparison to an LPS-stimulated 
positive control.  
Similar observations can be made when looking at the levels of immune stimulating (IL-
12p70) and immune suppressive (IL-10) cytokines that are produced by the mRNA 
sonoporated DCs 24 h after treatment (Figure 3). Sonoporation with GFP mRNA alone 
resulted in a significant increase in IL-10, but not IL-12p70 secretion. For both cytokines, 
inclusion of TriMix into the mRNA lipoplexes surrounding the microbubbles results in 
higher cytokine production. But still, the concentrations are significantly lower than when 
LPS was applied to induce maturation of the DCs.  
 
Figure 3. Cytokine production by mRNA-sonoporated DCs. The amounts of cytokines 
produced by untreated DCs (blank), DCs sonoporated with GFP mRNA alone, or in combination 
with TriMix (GFP+TriMix) and DCs that were matured with LPS were measured 24 h after cell 
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treatment. Figures show graphical representations of the levels of (A) IL-12p70 and (B) IL-10. 
Graphs are summaries of 2 independent experiments at n=3, results were analyzed via a one-
way ANOVA followed by a Bonferroni multiple comparison test. **p<0.01, ***p<0.001. 
In vivo induction of antigen-specific T cell proliferation by mRNA sonoporated DCs 
To assess the impact of mRNA sonoporation on the capacity of DCs to prime antigen-
specific CD8+ T cells, we performed an in vivo T cell proliferation study using chicken 
ovalbumin (OVA) as a model antigen. This makes use of an adoptive transfer of OT-I cells, 
which are transgenic T cells that carry a CD8 T cell receptor that specifically recognizes 
the OVA-derived peptide SIINFEKL when presented in MHC I. 24 h after adoptive OT-I 
cell transfer, tumor-free mice were vaccinated with mRNA sonoporated DCs, and the 
percentage proliferating OT-I cells was evaluated 5 days later. Results were normalized 
to the background signal in mice that received PBS instead of DCs. As demonstrated in 
Figure 4A, no aspecific OT-I proliferation was observed in the negative control group that 
received DCs sonoporated with GFP mRNA (3 ± 3%). When vaccination was performed 
with DCs sonoporated with antigen mRNA alone (OVA), this resulted in 31 ± 16% 
proliferation of OVA-specific CD8+ T cells, indicating efficient intracellular processing and 
presentation of OVA by the mRNA sonoporated DCs without additional stimulation of 
maturation. When OVA sonoporation was combined with phenotype-modulating stimuli, 
either by 2 h incubation of the sonoporated DCs with LPS (OVA/LPS as a positive control) 
or by sonoporation with OVA and TriMix mRNA (TriO), antigen-specific T cell proliferation 
increased to respectively 41 ± 15% and 48 ± 19%. Although there is a trend towards more 
extensive proliferation in the OVA/LPS and TriO groups, the observed differences were 
not statistically significant (p>0.05).  
In addition, we evaluated the functionality of the proliferating T cells, by performing a re-
stimulation with peptide. For this, a fraction of the proliferated OT-I cells were co-cultured 
in a 10:1 ratio with DCs that were pulsed with SIINFEKL peptide. 24 h later, the response 
of these restimulated T cells to the antigen-presenting DCs was evaluated by measuring 
the levels of IFNγ, an important mediator of CTL responses, in the co-culture supernatant. 
The results in Figure 4B display a similar trend to the proliferation results: T cells activated 
by DCs that received OVA mRNA via sonoporation produce significantly larger amounts 
of IFNγ compared to those stimulated with DCs sonoporated with GFP mRNA. After 
additional maturation by LPS incubation or sonoporation with TriMix, a trend towards 
higher IFNγ levels was observed.  
12 
 
 
Figure 4. In vivo proliferation of antigen-specific T cells. 1 day after adoptive OT-I transfer, 
mice were vaccinated with DCs sonoporated with GFP mRNA (negative control), OVA mRNA 
alone (OVA) or in combination with TriMix (TriO), or OVA-sonoporated DCs that were matured 
with LPS (OVA/LPS). Read-out was performed 24h later. Graphs show (A) percentages 
proliferating OT-I cells normalized to the background that was detected in mice that received a 
PBS injection. (B) levels of IFNγ measured 24h after restimulation of proliferated OT-I cells with 
peptide-pulsed DCs. Graphs are summaries of 2 independent experiments at n=3. Results were 
analyzed via a one-way ANOVA followed by a Bonferroni multiple comparison test. *p<0.05, 
***p<0.001. 
In vivo cytotoxic T cell response induction by mRNA sonoporated DCs 
Besides the capacity to stimulate antigen-specific T cells to proliferate, mRNA 
sonoporated DCs should be able to activate CD8+ T cells to cause antigen-specific lysis 
of target cells. To evaluate this, an in vivo CTL assay was performed, again using OVA 
as a model antigen. For this, tumor-free mice were vaccinated with mRNA sonoporated 
DCs and 5 days later, the animals were challenged with allogenic splenocytes that were 
either untreated (non-target cells) or pulsed with SIINFEKL peptide (target cells). The next 
day, the ratio of target cells versus non-target cells was studied as a measure for antigen-
specific lysis. The results, as represented in Figure 5, show 41 ± 31% OVA-specific lysis 
of target cells when mice were vaccinated with DCs sonoporated with OVA mRNA. LPS-
induced maturation of the DCs after sonoporation (OVA/LPS), could not further increase 
this percentage (39 ± 23%). Unexpectedly, DCs sonoporated with TriO were markedly 
less efficient in inducing antigen-specific lysis (25 ± 18%). Based on the proliferative 
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potential of TriO DCs as well as on their capacity to stimulate IFNγ-producing CD8+ T 
cells, more extensive CTL responses were expected.  
 
Figure 5. In vivo cytotoxic T cell assay. 5 days after vaccination of mice with DCs 
sonoporated with GFP mRNA (negative control), OVA mRNA alone (OVA) or in combination 
with TriMix (TriO), or OVA-sonoporated DCs that were matured with LPS (OVA/LPS), mice were 
challenged with target cells and non-target cells in a 1:1 ratio. The next day, the percentage 
antigens-specific lysis of target cells compared to non-target cells was measured. Graphs are 
summaries of 3 independent experiments at n=3. Results were analyzed via a one-way ANOVA 
followed by a Bonferroni multiple comparison test. *p<0.05. 
Therapeutic vaccinations with mRNA-sonoporated DCs 
Immune induction is a complex orchestrated response that relies on numberous 
synergistic components of both cellular and humoral immunity. Moreover, tumor-mediated 
suppression of immune responses, regulated by various immunosuppressive cell types 
such as myeloid-derived suppressor cells and regulatory T cells (Tregs) that reside in the 
tumor microenvironment, could potentially limit the therapeutic benefits of DC-based 
immunotherapy [22, 23]. Therefore, the impact of cancer vaccines can only truly be 
evaluated when all these different players are taken into account. For that reason, we 
assessed the potential of DCs sonoporated with antigen and TriMix mRNA in a therapeutic 
setting. For this, we examined the effect of vaccination with ex vivo mRNA sonoporated 
DCs in mice with pre-existing tumors. We initially opted for an OVA-expressing B16 
melanoma model (MO4). 10 days after tumor inoculation in the flank, tumors were 
palpable and the animals were randomized into 3 treatment groups based on the tumor 
volume (as shown in Supplemetary Data, Figure S1). Subsequently, the animals were 
given a s.c. injection with either DCs sonoporated with GFP mRNA (DC GFP, negative 
control, n=9), OVA mRNA (DC OVA, n=9), or sonoporated with TriMix and OVA mRNA 
(DC TriO, n=8). A second vaccination was performed 3 days later. When measuring tumor 
growth as a function of time, we observed a significant slow-down of tumor outgrowth in 
the DC OVA, and especially in the DC TriO group compared to the DC GFP group (Figure 
6). This translated in a prolongation of median survival of 41% and 82% for DC OVA and 
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DC TriO respectively. This indicates that antigen mRNA sonoporated DCs can induce 
potent antitumor immune responses in vivo, which can further be boosted by sonoporation 
with DC-modulating TriMix mRNA.  
 
Figure 6. Therapeutic vaccination of MO4-bearing mice with mRNA-sonoporated DCs. 10 and 13 
days after inoculation of mice with MO4 melanoma cells, therapeutic vaccinations with mRNA 
sonoporated DCs were performed. Graphs show tumor growth as a function of time for mice vaccinated 
with DCs sonoporated with (A) GFP mRNA (control), (B) OVA mRNA and (C) OVA mRNA and TriMix (DC 
TriO). A Kaplan-Meier survival curve is shown in (D). 
These therapeutic vaccination experiments were repeated in a different tumor model, 
expressing the same antigen. For this, mice were inoculated with E.G7-OVA, which are 
OVA-expressing lymphoma cells. Randomization was done based on tumor volume at 
day 10 after tumor inoculation (as shown in Supplemetary Data, Figure S2). Once more, 
two therapeutic vaccinations were performed at 10 and 14 days after tumor inoculation. 
In addition to the 3 treatment groups described in the previous experiment, we included a 
group that received OVA mRNA sonoporated DCs that were additionally matured with 
LPS for 2 h prior to injection (DC OVA/LPS) (n=6 in all groups). This way, we aimed to 
compare the therapeutic effects of TriMix sonoporation to the use of a known and potent 
maturation inducer. In accordance to the previous experiment, the tumor growth curves in 
Figure 7 indicate that sonoporation with antigen results in a significant delay of tumor 
outgrowth, resulting in a 58% increase in median survival. Interestingly, the slow-down of 
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tumor growth was markedly shorter-lived in the DC OVA/LPS group compared to their 
unstimulated counterparts (DC OVA). This resulted in merely 35% prolongation of median 
survival of animals in the DC OVA/LPS group compared to the DC GFP group. In contrast, 
stimulation of antigen presentation by sonoporation with OVA and TriMix mRNA, resulted 
in a pronounced effect on tumor growth: median survival was more than doubled (212% 
increase), and complete tumor regression was observed in 2/6 animals in the DC TriO 
group.  
 
Figure 7. Therapeutic vaccination of E.G7-OVA-bearing mice with mRNA-sonoporated 
DCs. 10 and 14 days after inoculation of mice with E.G7-OVA lymphoma cells, therapeutic 
vaccinations with mRNA sonoporated DCs were performed. Graphs show tumor growth as a 
function of time for mice vaccinated with DCs sonoporated with (A) GFP mRNA (control), (B) 
OVA mRNA, (C) OVA mRNA and TriMix (DC TriO) and (D) OVA mRNA followed by a 2h 
maturation with LPS (DC OVA/LPS). A Kaplan-Meier survival curve is shown in (E). 
These surviving animals, as well as two naïve control mice, were rechallenged with E.G7-
OVA tumor cells 42 days after the first tumor inoculation. This to evaluate whether durable 
antitumor immunity was induced by the vaccinations. Indeed, in comparison to the control 
mice where rapid tumor growth was observed, the DC TriO vaccinated mice were 
protected against a second injection with the same tumor (Figure 8). To prove that this 
protective immunity is antigen-specific, we challenged these animals with a different tumor 
(MO4 melanoma instead of the initial lymphoma) that expresses the same antigen. Once 
more, no tumor growth could be detected in the DC TriO vaccinated animals in contrast 
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to 3 naïve control mice. Thus, vaccination with DC TriO can induce antigen-specific 
immunological memory, that is capable of protecting tumor-free survivors against tumor 
recurrence.  
 
Figure 8. Rechallenge of tumor-free DC TriO treated mice. The two E.G7-OVA challenged 
mice that showed complete tumor regression after two vaccinations with DC TriO , were 
rechallenged with E.G7-OVA and MO4 tumor cells on day 42 and day 80 after initial tumor 
inoculation, respectively. As controls, naïve, non-vaccinated mice were injected with the same 
tumor load. 
DISCUSSION 
In continuation of our previous report on the use of mRNA-loaded microbubbles and 
ultrasound for the transfection of DCs in vitro [13], we further investigated if antigen 
transfer into DCs via mRNA sonoporation could result in the induction of antitumor 
immune responses. For this, it was crucial to not only deliver antigen mRNA to the DCs, 
but at the same time to induce a shift in activity of these cells, in order to make them more 
effective in antigen presentation to naïve T cells. This should in turn result in protection 
against tumor growth. To allow this antigen-loading and maturation to occur 
simultaneously, we included TriMix into the mRNA-lipoplexes that surround the 
microbubbles, and performed sonoporations with 4 mRNA sequences in total.  
First of all, we were able to show that sonoporation with multiple mRNAs is feasible. Upon 
sonoporation with GFP mRNA and TriMix, both GFP expression as well as a slight but 
significant up-regulation of maturation marker expression by DCs was observed. 
However, sonoporation with TriMix lead to a reduction in the percentage of GFP-
expressing cells, which is probably due to limitations in the amount of mRNA that can be 
loaded onto the microbubble surface. For sonoporation with TriMix, a four-fold increase in 
total amount of mRNA, and therefore in amount of mRNA-lipoplexes is required. However, 
the number of binding spaces on the bubble surface is limited [24]. Therefore, it is likely 
that in the TriMix conditions, complete microbubble saturation occurs, resulting in the 
presence of a substantial portion of free mRNA-lipoplexes in the medium. In our previous 
reports, we demonstrated that the highest transfection efficiencies could be reached when 
the lipoplexes are physically attached to the microbubbles and not just co-delivered [12, 
25]. For that reason, sonoporation with multiple mRNAs could lead to a lower protein 
expression. In addition, there is the possibility that the co-transfection with multiple RNAs 
results in competition for mRNA translation. This theory is supported by the observations 
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of Chen et al., who also reported a drop in transfection efficiency 2 mRNAs were co-
electroporated in DCs compared to electroporation of each of these mRNAs alone [26]. 
This was also reported by Bonehill and colleagues who reported that upon electroporation 
of DCs with TriMix the number of mRNA-expressing DCs was always slightly decreased 
when two or three mRNAs were co-electroporated, in comparison to the electroporation 
of each mRNA alone [16]. This might indicate that there is a limit to the amount of mRNA 
that can be transferred into the cells. This raises the question whether this reduced 
transfection efficiency could limit the use of antigen mRNA and TriMix sonoporation. To 
answer this, it is important to take the therapeutic studies performed with TriO 
sonoporated DCs into account. These confirm that a higher transfection efficiency does 
not necessarily result in more potent immune responses. Indeed, DCs sonoporated with 
antigen mRNA alone, which allows higher antigen expression, result in less powerful 
immune responses, even after additional LPS-maturation, compared to TriO sonoporated 
DCs, where the amount of antigen that is produced by the DCs is lower. This discrepancy 
between transfection efficiency and immunogenicity was previously reported by 
Grünebach et al., who postulated that it is important to realize that T cell receptors can 
detect antigens at much higher sensitivity than any routinely used analytical instrument in 
the lab [27]. In addition, T cell activation does not only depend on the presence of the 
antigen. Only when the antigens are presented to T cells by fully functional and mature 
DCs, can this result in effective T cell activation [8].  
Thus, it is crucial to obtain antigen-loaded DCs with a mature phenotype. In accordance 
to our previous reports, mRNA sonoporation as such, without incorporation of additional 
immune stimulants, readily results in a distinct up-regulation of maturation marker 
expression at the DC surface. This in contrast to mRNA electroporation, which is 
considered the golden standard for mRNA transfer into DCs in vitro, where no effects on 
the DC maturation status were observed [16, 21]. Two possible mechanisms might explain 
this sonoporation-induced maturation. First of all, sonoporation is a physical transfection 
method, where pores are created as a result from shear forces and violent microbubble 
movements [28]. DCs are known to be sensitive to shear forces, and can already up-
regulate maturation markers upon stress due to pipetting and centrifugation [29]. Thus, 
the shear stress induced by sonoporation could contribute to the observed phenotypical 
changes. In addition, sonoporation was reported to influence Ca2+ signaling within cells 
[28, 30]. Importantly, increased intracellular Ca2+ concentrations were also reported as 
one of the early events after LPS stimulation of mouse bone marrow-derived DCs [31]. 
Another possibility is direct triggering of innate immune responses by the cationic lipids 
(in this case DOTAP) within the mRNA lipoplexes, via TLR4 ligation. This, charge-related 
TLR activation was previously reported for DOTAP-containing lipoplexes as well as for 
various cationic polymers that are routinely used as transfection reagents [32, 33]. Likely, 
the observed effects are caused by a combination of these different mechanisms.  
Much to our surprise, this limited maturation induced by antigen sonoporation alone 
already rendered the cells capable of inducing potent T cell proliferation, CTL responses 
and antitumor immune effects in tumor-free animals in vivo. Therefore, it was crucial to 
evaluate whether or not sonoporation with TriMix had an added value on the induced 
immune responses. By looking at the relative maturation marker expression and cytokine 
production by mRNA sonoporated DCs in vitro, it would appear that the contribution of 
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TriMix is limited, especially in comparison to maturation by LPS as a positive control. A 
possible explanation for this could be the transfection efficiency that can be obtained with 
mRNA sonoporation. Although this technique allows substantial transfection of DCs, its 
efficiency is still relatively low in comparison to electroporation, where over 90% of the 
DCs can be transfected with mRNA. Indeed, with mRNA electroporation, TriMix does 
result in a significant up-regulation of maturation markers and cytokine expression, as 
previously reported by Bonehill et al. [17]. In addition, based on the results obtained in the 
OT-I proliferation assay and the in vivo CTL assay, it would appear that TriO sonoporation 
works fine to enhance the quantity of antigen-specific CD8+ T lymphocytes (i.e. numbers 
of proliferating cells), but at a first glance, their quality (i.e. cytolytic activity) is not as good 
as when OVA or OVA/LPS are used. However, it should be noted that these experiments 
were performed in naïve, healthy mice and not in tumor-bearing animals. In the latter, it 
was obvious that TriO sonoporation was superior, and resulted in the most pronounced 
slowdown of tumor outgrowth and prolongation of median survival. Importantly, TriO DCs 
could even induce complete regression in 30% of the vaccinated animals, resulting in 
long-lasting protection against (re)challenges with tumor cells that express the vaccine 
antigen (in this case OVA).  
A possible explanation for this discrepancy between immune responses observed in 
healthy versus tumor-bearing animals, is the existence of pre-vaccination antitumor 
immune responses. It was shown by Germeau and colleagues that large numbers of 
antitumor T cells are already present within melanoma patients prior to vaccination with 
tumor antigens. However, these natural pre-vaccine immune responses are often too 
weak to result in tumor rejection or even a reduction in tumor growth, due to the various 
immune suppressive mechanisms that occur within the tumor microenvironment [34]. 
Vaccination can then aid in boosting these spontaneous immune responses, either by 
aiding to overcome tumor-induced immune suppression, by re-activating anergic tumor-
reactive T cells at the tumor site, or by inducing new antitumor CTL clonotypes (probably 
due to additional antigen release from attacked tumor cells) [3, 35]. This priming of the 
immune system by a growing tumor could explain why the immunogenicity of the mRNA 
sonoporated DCs was more pronounced in a therapeutic setting.  
As to the question what could explain the superiority of TriMix over LPS in the therapeutic 
vaccination experiment, there are a number of possible causes. In essence, it is important 
to always keep in mind that immune responses are regulated in a complex manner, 
involving numerous different cell types. As discussed earlier, the effectiveness of a DC 
vaccine is not only determined by its capacity to induce effector CD8+ T cells. Major factors 
that limit the potency of cancer vaccines are the hostile tumor microenvironment and the 
presence of Tregs that counteract CTL activity [36]. Therefore, undermining these 
immunosuppressive mechanisms might be the key to successful cancer vaccines. 
Interestingly, previous research by Pen et al. exposed TriMix as a potential tool in 
subverting Treg effects. They demonstrated that CD8+ T cells that were preactivated by 
TriMix electroporated DCs were protected against Treg suppression. What was more, 
TriMix electroporated DCs could reprogram Tregs towards a Th1 phenotype, thus 
reinforcing cellular immunity against the tumor [37]. Based on these observations, it is 
quite likely that in the therapeutic vaccination setting, the superior antitumor effects of TriO 
DCs could be, at least partially, attributed to a reduction of Treg-mediated immune 
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suppression. Of course, many other cell types are involved in the regulation of antitumor 
immunity, and the effects of TriMix on these different cells is not yet known. For instance, 
it might be possible that TriMix transfected DCs could stimulate natural killer (NK) cells, 
which act synergistically with CTLs and were recently reported to mount antigen-specific 
responses that can lead to long-term memory [38-41].  
We reported that the transfection efficiencies that can be reached with mRNA 
sonoporation are significantly lower than when mRNA is electroporated into DCs, however 
it should be noted that the importance of mRNA sonoporation as a transfection technique 
lies within its possible in vivo applicability [42, 43]. Commercially available microbubble 
contrast agents were shown to migrate to the tumor-draining lymph nodes upon 
intradermal injection around the tumor of breast cancer patients [15]. This makes them 
useful to identify and localize sentinel lymph nodes in a non-invasive manner, using 
contrast-enhanced ultrasound imaging (CEUS). In addition, their lymphatic uptake is 
particularly interesting, since lymph nodes harbor large numbers of immune cells, 
including a substantial fraction of DCs [44, 45]. Therefore, microbubbles could be used for 
image-guided in vivo vaccination. The immunotherapy could then consist of a 
subcutaneous injection of mRNA-loaded microbubbles, of which the migration to the 
draining lymph nodes could be visualized using CEUS. Once the microbubbles and hence 
the mRNA are localized within the lymph nodes, higher intensity ultrasound pulses could 
induce localized microbubble implosion, resulting in spatiotemporally controlled delivery 
of both antigen mRNA and immunomodulating TriMix to intranodal DCs. This could allow 
a minimally invasive vaccination procedure that could substantially reduce the costs and 
laborious procedures that are currently associated with the production of ex vivo 
generated DC vaccines. Of course, this will require a thorough optimization of microbubble 
and mRNA dosages and ultrasound parameters, as these greatly influence the 
transfection efficiency with microbubbles and ultrasound in vivo [46].  
CONCLUSIONS 
Taken together, DCs that were sonoporated with antigen mRNA via mRNA loaded 
microbubbles and ultrasound can induce potent antigen-specific immune responses in 
vivo. Sonoporation with TriMix, to further modulate the DC’s antigen-presenting 
functionality, could be used to further augment immunity. Especially in a therapeutic 
setting, vaccination with antigen and TriMix mRNA sonoporated DCs resulted in a 
significant reduction in tumor growth, leading to a marked increase in overall survival and 
long-lasting antigen-specific protection against tumor recurrence. Therefore, sonoporation 
could be a useful tool in the future development of in vivo DC vaccines.  
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Figure S1. Randomization for the MO4 therapeutic vaccination experiment. 10 days after 
MO4 tumor inoculation, mice were randomized in three treatment groups based on tumor 
volume. Tumor volumes were analyzed via a one-way ANOVA followed by a Bonferroni multiple 
comparison test. No significant differences were observed at the 5% significance level.  
 
Figure S2. Randomization for the E.G7-OVA therapeutic vaccination experiment. 10 days 
after E.G7-OVA tumor inoculation, mice were randomized in four treatment groups based on 
tumor volume. Tumor volumes were analyzed via a one-way ANOVA followed by a Bonferroni 
multiple comparison test. No significant differences were observed at the 5% significance level. 
